Comorbidity indices in people with HIV and considerations for coronavirus disease 2019 outcomes
Alan Winston, Davide De Francesco, Frank Post, Marta Boffito, Jaime Vera, Ian Williams, Jane Anderson, Patrick W G Mallon, Caroline A Sabin, POPPY Study Group, Alan Winston, Davide De Francesco, Frank Post, Marta Boffito, Jaime Vera, Ian Williams, Jane Anderson, Patrick W G Mallon, Caroline A Sabin, POPPY Study Group
Abstract
Objective: To determine comorbidity indices in people with HIV (PWH) and lifestyle-similar HIV-negative controls.
Design: Cross-sectional analysis of the Pharmacokinetic and clinical Observations in PeoPle over fiftY cohort study in the United Kingdom and Ireland.
Methods: The Elixhauser Comorbidity Index (ECI), Charlson Comorbidity Index and the Comorbidity Burden Index were compared between older PWH and HIV-negative controls using the Mann-Whitney U test; the magnitude of the difference between groups was quantified using the r effect size.
Results: The 699 PWH and 304 HIV-negative controls were predominantly male (87.5% vs. 64.0%), white (86.3% vs. 90.0%) and had median ages of 57 and 58 years, respectively. Among PWH, the median (interquartile range) CD4 T-cell count was 624 (475, 811) cells/μl; 98.7% were on antiretroviral therapy. The median (interquartile range) ECI was 0 (0, 8) and 0 (-3, 1), Charlson Comorbidity Index was 2 (1, 5) and 1 (0, 1) and Comorbidity Burden Index 8.6 (2.2, 16.8) and 5.9 (0.6, 10.8), respectively. While all three indices were significantly higher in PWH than in controls (P < 0.001 for each), the magnitude of the differences between the two groups were small to medium, with effect sizes (95% confidence interval) of 0.21 (0.16, 0.27), 0.38 (0.32, 0.42) and 0.18 (0.11, 0.23), respectively.
Conclusion: These three comorbidity indices are higher in PWH compared with HIV-negative controls, although the magnitude of differences between groups were small. Differences in the ECI, reportedly associated with poorer coronavirus disease 2019 outcomes, were driven by more individuals with HIV being within the higher end of the range.
Conflict of interest statement
There are no conflicts of interest.
Figures
References
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8:475–481..
- Wang K, Zuo P, Liu Y, Zhang M, Zhao X, Xie S, et al. Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China. Clin Infect Dis 2020; May 3: ciaa538. Published online 2020 May 3.
- Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998; 36:8–27..
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373–383..
- Poses RM, McClish DK, Smith WR, Bekes C, Scott WE. Prediction of survival of critically ill patients by admission comorbidity. J Clin Epidemiol 1996; 49:743–747..
- Lovell N, Maddocks M, Etkind SN, Taylor K, Carey I, Vora V, et al. Characteristics, symptom management and outcomes of 101 patients with COVID-19 referred for hospital palliative care. J Pain Symptom Manage 2020; 60:e77–e81..
- Perez-Guzman PN, Daunt A, Mukerjee S, Crook P, Forlano R, Kone MD, et al. Clinical characteristics and predictors of outcomes of hospitalised patients with COVID-19 in a London NHS Trust: a retrospective cohort study. 2020; London:School of Public Health, Imperial College London COVID-19, 10.25561/7861310.25561/78613. [Accessed 26 June 2020].
- Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 2014; 59:1787–1797..
- Bagkeris E, Burgess L, Mallon PW, Post FA, Boffito M, Sachikonye M, et al. Cohort profile: the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study. Int J Epidemiol 2018; 47:1391–1392e..
- De Francesco D, Verboeket SO, Underwood J, Bagkeris E, Wit FW, Mallon PWG, et al. Patterns of co-occurring comorbidities in people living with HIV. Open Forum Infect Dis 2018; 5:ofy272.
- van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care 2009; 47:626–633..
- Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173:676–682..
- Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30:473–483..
- Ware J, Kosinski M, Keller S. SF-36 physical and mental summary scales: a user's manual. Boston, Massachusetts, USA:The Health Institute; 1994.
- De Francesco D, Verboeket SO, Verheij E, Underwood J, Bagkeris E, Wit FWNM, et al. Development and validation of a comorbidity index for people living with HIV and its ability to predict frailty and mortality. In: 17th European AIDS Conference. Basel, Switzerland; 2019.
- Blanco JL, Ambrosioni J, Garcia F, Martinez E, Soriano A, Mallolas J, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV 2020; 7:e314–e316..
- Drain PK, Garrett N. SARS-CoV-2 pandemic expanding in sub-Saharan Africa: considerations for COVID-19 in people living with HIV. EClinicalMedicine 2020; May; 22: 100342. Published online 2020 Apr 22.
- Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020; 382:1787–1799..
Source: PubMed